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Abstract 
DiGeorge syndrome (22q11.2 deletion) is associated with several neurologic disorders includ-
ing structural abnormalities involving brain and spine, movement disorders, and epilepsy. Pro-
gressive spastic paraparesis has not been reported with DiGeorge syndrome. We report an 
individual in which DiGeorge syndrome was associated with progressive spastic paraparesis. 
This report extends the clinical phenotype of DiGeorge syndrome and presents the differential 
diagnosis of progressive spastic paraparesis in individuals with DiGeorge syndrome which pro-
vides insight into the clinical evaluation of such individuals. © 2020 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
First described in 1965, DiGeorge syndrome is the result of a deletion on chromosome 22 
at 22q11.2 involving the TBX1 gene, which disrupts embryonic development of the third and 
fourth pharyngeal arches. Specifically, TBX1 is considered to be the critical gene associated 
with the majority of features associated with 22q11.2 deletion syndrome [1, 2]. The incidence 
of 22q11.2 deletion syndrome is approximately 1 in 3,000 to 1 in 6,000 live births and 90–
95% are de novo [2]. Initial descriptions of DiGeorge syndrome included thymic hypoplasia, 
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hypocalcemia, cardiac defects, and dysmorphic facies [3]. Subsequently, the phenotype has 
been expanded variably to include autoimmune disease, intellectual disability, psychiatric dis-
orders, and skeletal, renal, gastrointestinal, and genitourinary abnormalities [2]. 
Multiple neurologic conditions are associated with DiGeorge syndrome. General neuro-
logic deficits include decreased truncal stability, hypotonia, increased tendon reflexes, and 
clonus. Brain and spine malformations include decreased brain volume, polymicrogyria, gray 
matter heterotopia, and tethered cord. Movement disorders include early onset Parkinsonism 
as well as difficulties with balance and coordination. The risk of developing epilepsy is in-
creased in subjects with DiGeorge syndrome. As noted above, DiGeorge syndrome may be as-
sociated with neuropsychiatric disorders including intellectual disability, anxiety, autism 
spectrum disorders, attention deficit hyperactivity disorder, schizophrenia, and dementia [4].  
Case Presentation 
Following a complicated gestation (mother unable to recall exact nature of complications) 
and uneventful delivery, this individual underwent ligation of her patent ductus arteriosus to 
repair a perimembranous ventricular septal defect in infancy. She required constant hospital-
izations for upper respiratory infections as a child but had normal attainment of neurodevel-
opmental milestones. Mild cognitive impairment became evident around third grade, requir-
ing special education classes. At age 16, she developed progressive gait disturbance. Symp-
toms consistent with myoclonic seizures led to treatment with clonazepam. A diagnosis of 
spinocerebellar ataxia was entertained. She graduated from high school. In her 20s, her recur-
rent upper respiratory infections were thought to be due to hypogammaglobulinemia, for 
which she was treated with recurrent infusions of intravenous immunoglobulin. She was also 
noted to have chronic hypocalcemia. 
She came under our care at age 33, at which point her neurological examination showed 
marked, bilaterally symmetric, lower extremity hyperreflexia, spasticity, weakness; slight 
ataxia in the upper extremities; and extensor plantar reflexes. She was not able to stand. Ex-
traocular movements and speech were normal. At this point, the individual was felt to have a 
slow progressive spastic paraparesis syndrome of unknown etiology and the focus remained 
on symptom management for several years. At age 40, she began experiencing a decline in 
proximal strength and cognition. Her neurologic exam at this point revealed marked weakness 
in the lower extremities with fairly good power in the arms. Sensation was minimally reduced 
in the legs to vibration and proprioception and light touch distally. Muscle stretch reflexes 
were pathologically hyperactive at the knees with clonus but absent ankle jerks. Muscle 
stretch reflexes were mildly hyperactive in the arms and at the jaw. She did not have spastic 
speech or a pseudobulbar affect. She had prominent extensor plantar responses bilaterally. 
Urostomy and colostomy were performed at age 37 to treat neurogenic bladder and 
chronic diarrhea. Chronic somatic pain complaints which underwent extensive evaluation and 
diagnostics were also a constant feature of her presentation. 
Given the absence of obvious cerebellar signs that would be consistent with spinocerebel-
lar ataxia, several other possibilities were explored. Evaluation of B12 deficiency, vitamin E 
deficiency, thyroid dysfunction, zinc disturbance, copper deficiency, copper excess, arsenic ex-
cess, lead excess, mercury excess, and NMO antibodies all failed to reveal a specific cause. 
Oxysterols, lysosomal enzymes, cholestanol, and very-long-chain fatty acids were also tested 
and were within normal ranges. Her lumbar puncture results were within normal limits 
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including normal IgG and no oligoclonal bands. Human T-cell lymphotropic virus I/II testing 
was negative. 
Genetic testing included specific testing for Friedreich ataxia, which revealed one FXN 
gene with a full expansion of 1,200 GAA repeats. The other allele was normal with 13 GAA 
repeats. Further mitochondrial genome analysis and mitochondrial nuclear gene testing iden-
tified a heterozygous 2.6 Mb deletion at 22q11.2 including both the HIRA (TUPLE) and TBX1 
genes, consistent with a diagnosis of 22q11.2 microdeletion syndrome or DiGeorge syndrome. 
This diagnosis was felt to explain her history of cardiac defects, hypocalcemia, and hypogam-
maglobulinemia. However, the 22q11.2 deletion was not felt to explain all of her neurologic 
symptoms. Whole exome sequencing (WES) (GeneDX, USA) was performed, which did not find 
any additional pathogenic variants associated with the reported phenotype or a point muta-
tion in her second FXN gene. WES also did not identify any changes in genes associated with 
hereditary spastic paraparesis.  
Her brain MRI at 42 years of age indicated nonspecific areas of signal abnormality within 
the periventricular and subcortical white matter. This was slightly increased in comparison to 
an MRI at 33 years of age, but without callosal and pericallosal disease commonly seen in mul-
tiple sclerosis. There was a chronic right frontal periventricular lacunar infarction without 
evidence of superimposed acute infarction. An MRI of her entire spine at 33 and 38 years of 
age showed a small spinal cord without any signal abnormality. An MRI of her lumbar spine 
at 41 years of age showed diffuse muscle atrophy. Finally, an MRI of her cervical spine at 42 
years of age showed multilevel cervical spondylosis. 
EEGs performed at ages 36, 38, 42, and 44 years of age were normal. 
Neuropsychological testing performed at 43 years of age revealed impaired function 
across nearly all cognitive domains including memory, attention, visuo-construction, psycho-
motor speed, and executive functions, thought to be consistent with major neurocognitive dis-
order. Her premorbid IQ was determined to be 73 using the Wechsler Test of Adult Reading, 
indicating borderline to mild cognitive impairment. 
Finally, EMGs were performed at 41 and 44 years of age on the more symptomatic left 
lower extremity. Examination was limited by the patient being unable to transfer from her 
wheelchair and wishing to remain in her chair for the test. Motor nerve conduction studies 
revealed a low amplitude peroneal response with normal latency and conduction velocity. 
Sensory nerve conduction study showed no response. Limited needle examination due to pa-
tient’s wheelchair dependence revealed mildly large motor unit potentials and irritability of 
the medial gastrocnemius. Deltoid muscle was normal. The results supported the diagnosis of 
axonal polyneuropathy with no indication of myopathy. 
Conclusion 
Here, we present a case of a 45-year-old woman with genetically confirmed DiGeorge syn-
drome and progressively worsening spastic paraparesis of unknown etiology. Mitochondrial 
disease, copper deficiency, vitamin deficiency, heavy metal excess, multiple sclerosis, adreno-
myeloneuropathy, cerebrotendinous xanthomatosis, Niemann-Pick disease, Friedreich ataxia 
and neuromyelitis optica were ruled out. Imaging, lumbar puncture, EMG, and genetic testing 
also failed to reveal a specific cause. Thus, we propose that her neurologic manifestations are 
related to DiGeorge syndrome and, to our knowledge, this is a unique finding not previously 
described in the literature.  
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